Fig. 5
ADE capacities of JEV-NTE- or DV/ZV-NTE-immune sera in vivo. A Schematic representation of the in vivo ADE study design. AG129 mice were first i.p. injected with PBS, pre-immune sera, 5 µg of mAb 4G2, JEV-NTE- or DV/ZV-NTE-immune sera, then 24 h later i.p. challenged with 104 FFU of DENV-4. Blood samples were collected at day 3 post-infection and survival rates were monitored for 30 days. B Platelets in the blood were counted using an automated hematology analyzer. C Viremia levels in the serum were measured by focus-forming assay. Each dot represents the viremia level of an individual mouse. D Survival rates were monitored daily for 30 days. The numbers of animals (n) in each group are shown. Statistical differences in survival rates were evaluated by the log-rank test. The data are representative results of two independent experiments. Data are presented as the means ± SD of two independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 [by Log-rank (Mantel-Cox) test or One-way ANOVA]. ns not significant